Rupert Martin Bauersachs

from Wikipedia, the free encyclopedia

Rupert Martin Bauersachs is a German angiologist and internist, director of the Clinic for Vascular Medicine - Angiology at the Darmstadt Clinic and professor at the Goethe University in Frankfurt .

Life

Bauersachs studied medicine from 1977 to 1983 at the Ludwig Maximilians University in Munich and the Technical University of Munich , and in 1981 at the Oxford University Medical School. In 1984 he was awarded a Dr. med. PhD. From 1984 to 1985 he was a research assistant at the Institute of Pharmacology at the Technical University of Munich and from 1985 to 1987 Research Fellow of the American Heart Association at the Physiological Institute of the University of Southern California Los Angeles . From 1987 to 1993 he completed specialist training as an internist at the Munich-Bogenhausen Clinic, and from 1993 to 1999 he trained as an angiologist, diabetologist , phlebologist and hemostaseologist at the universities of Frankfurt and Mainz. In 1999 he completed his habilitation on ischemia and reperfusion disorders and was authorized to train in angiology . In 1999 he was recognized as a Fellow of the International Union of Angiology. From 1999 to 2003, Bauersachs took over the provisional management of the angiology focus at the Goethe University in Frankfurt am Main, and in 2000 co-founded the first German university vascular center at the University of Frankfurt. In 2003 he was appointed director of the Medical Clinic IV for Angiology at the Darmstadt Clinic and co-founder of the Darmstadt Vascular Center. In 2004, Bauersachs received an extraordinary professorship at the University of Frankfurt am Main and in 2012 a visiting professorship for Vulnerable Individuals and Populations - VIP at the Center for Thrombosis and Hemostasis (CTH) at the University of Mainz. He is the scientific director of the Thrombosis Action Alliance, which he helped initiate in 2014, and which u. a. organizes World Thrombosis Day in Germany .

Clinical focus

Clinical-scientific contribution

At the end of the 1990s, Bauersachs advocated outpatient therapy for deep vein thrombosis in Germany and ten years later acute therapy and extended secondary prophylaxis for thrombosis with direct oral anticoagulants (DOACs). Another ten years later, the HOT-PE study group with Bauersachs was able to show that the outpatient or short inpatient treatment of pulmonary embolism with a DOAK can also be carried out safely and effectively. As a new approach to anticoagulation, a team of researchers with Bauersachs examined the inhibition of factor XIa with osocimab for the first time. In patients after knee replacement, the medium and high dosages of osocimab were comparable with enoxaparin, and were superior when used before surgery.

For the neglected clinical picture of superficial venous thrombosis ( thrombophlebitis ), a team with Bauersachs was able to establish an evidence-based therapy for this common disease in 2010. For vulnerable thrombosis populations, such as pregnant women, the elderly, kidney failure or cancer, Bauersachs was able to lead or help shape new studies that are relevant to the guidelines. In the VOYAGER study, which Bauersachs led together with W.Hiatt, the antithrombotic management after vascular surgery or catheter surgery was prospectively examined in a randomized study in PAD patients. The vascular dose of (→) rivaroxaban together with (→) acetylsalicylic acid could reduce leg and cardiovascular complications; however, the bleeding rates were increased compared to acetylsalyic acid alone.

One of the concerns of Bauersachs is the critical implementation of the research results in clinical practice, also with the aim of avoiding over- and undersupply, for example in thrombophilia diagnosis, prescription of oral contraceptives, diagnosis of thrombosis including gender-specific aspects, for the quality of care, and Patient preference, as well as in the complex situation of anticoagulation in the context of medical interventions. An important field of activity for him is the awareness, education and quality of life of patients in vascular diseases, for example thrombosis, pulmonary embolism or peripheral arterial occlusive disease. As the scientific director of the Thrombosis Alliance, he was instrumental in the development of an easy-to-implement algorithm for the complex question of the duration of anticoagulation in venous thromboembolism ("anticoagulation traffic light"). Bauersachs is working on various national and international guidelines and position statements on thrombosis management in pregnancy, contraception, periinterventional anticoagulation, antiphospholipid syndrome, carotid stenosis, PAOD and other vascular diseases.

Memberships

Publications

Web links

Individual evidence

  1. ^ A b Rupert Martin Bauersach's CV German Society for Phlebology
  2. ^ Visiting scientist at the CTH, Mainz University Medical Center
  3. ^ Thrombosis Action Alliance
  4. ↑ World Thrombosis Day
  5. ↑ Bauersachs R, Lindhoff-Last E, Wolff U, Ehrly A: Current management of deep vein thrombosis. Med World 1998 1998; 49: 194-214
  6. ↑ Bauersachs RM, Lindhoff-Last E, Ehrly AM: [Ambulatory treatment of an acute pulmonary artery embolism in fresh thigh vein thrombosis using low-molecular-weight heparin]. Dtsch Med Wochenschr 1999; 124: 1485-1488
  7. ↑ Bauersachs R, Berkowitz SD, Brenner B, et al: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510
  8. ↑ Barco S, Lankeit M, Binder H, et al: Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial. Thromb Haemost 2016; 116: 191-197
  9. ↑ Weitz JI, Bauersachs R, Becker B, et al: Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA 2020; 323: 130-139
  10. ↑ Décousus H, Leizorovicz A, Bauersachs R, et al: Fondaparinux for the treatment of superfical-vein thrombosis in the legs N Engl J Med 2010; 363: 1222-1232
  11. ↑ Beyer-Westendorf J, Schellong SM, Gerlach H, et al: Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomized, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017; 4: e105-e113
  12. ↑ Bauersachs RM, Dudenhausen J, Faridi A, et al: Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98: 1237-1245
  13. ↑ Leizorovicz A, Siguret V, Mottier D, et al: Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep (R) in Renal Insufficiency Study (IRIS). Thromb Res 2011; 128: 27-34
  14. ↑ Lee AY, Bauersachs R, Janas MS, et al: CATCH: a randomized clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013; 13:284
  15. ↑ Bauersachs R, Lee AYY, Kamphuisen PW, et al: Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study. Thromb Haemost 2018; 118: 914-921
  16. ↑ Schellong SM, Gerlach HE, Tebbe U, et al: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: An analysis of the CERTIFY study. Thromb Res 2011; 128: 417-421
  17. ↑ Bauersachs R, Schellong SM, Haas S, et al: CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thromb Haemost 2011; 105: in press
  18. ↑ Bauersachs RM: Guidelines for the management of cancer and thrombosis - Special aspects in women. Thromb Res 2015; 135 Suppl 1: S16-22
  19. ↑ Agnelli G, Becattini C, Meyer G, et al: Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. New England Journal of Medicine 2020
  20. ↑ Bonaca MP, Bauersachs RM, Anand SS, et al: Rivaroxaban in Peripheral Artery Disease after Revascularization. New England Journal of Medicine 2020:
  21. ↑ Bauersachs R, Kuhl H, Lindhoff-Last E, Ehrly AM: [Risk of thrombosis with oral contraceptives: value of a thrombophilia screening test]. Vasa 1996; 25: 209-220
  22. ↑ Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H: Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy. Vasa 2018; 47: 441-450
  23. ↑ Schellong S, Gerlach H, Hach-Wunderle V, et al: Diagnosis of Deep Vein Thrombosis: Adherence to guidelines and outcomes in real world health care. Thrombosis and Hemostasis 2009; 102: 1234-1240
  24. ↑ Bauersachs RM, Riess H, Hach-Wunderle V, et al: Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis. Thromb Haemost 2010; 103: 710-717
  25. ↑ Mueller S, Pfannkuche M, Breithardt G, et al: The quality of oral anticoagulation in general practice in patients with atrial fibrillation. Eur J Intern Med 2014; 25: 247-254
  26. ↑ Boettger B, Wehling M, Bauersachs R-, Amann S, Wilke T: Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function: results of an observational study J Public Health 2014:
  27. ↑ Bottger B, Thate-Waschke IM, Bauersachs R, Kohlmann T, Wilke T: Preferences for anticoagulation therapy in atrial fibrillation: the patients' view. J Thromb Thrombolysis 2015:
  28. ↑ Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R: Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient 2017; 10: 17-37
  29. ↑ Bauersachs RM, Schellong S, Haas S, et al: Bridging the oral anticoagulation in interventional procedures. Dtsch Arztebl 2007; 104: 1237-1244
  30. ^ Bauersachs RM, Gogarten W, Hach-Wunderle V, et al: [Perioperative management of anticoagulation with rivaroxaban]. Clinic doctor 2012; 41: 424-431
  31. ↑ Schellong SM, Riess H, Spannagl M, et al: [Bridging anticoagulation in patients receiving vitamin K antagonists: Current status]. Anesthesiologist 2018; 67: 599-606
  32. ↑ Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C: The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65-73
  33. ↑ Monreal M, Agnelli G, Chuang LH, et al: Deep Vein Thrombosis in Europe-Health-Related Quality of Life and Mortality. Clin Appl Thromb Hemost 2019; 25: 1076029619883946
  34. ↑ a b Chuang LH, Cohen AT, Agnelli G, et al: Comparison of quality of life measurements: EQ-5D-5L versus disease / treatment-specific measures in pulmonary embolism and deep vein thrombosis. Qual Life Res 2019; 28: 1155-1177
  35. ↑ Chuang LH, van Hout B, Cohen AT, et al: Deep-vein thrombosis in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res 2018; 170: 165-174
  36. ↑ Bauersachs R, Debus S, Nehler M, et al: A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease. Angiology 2019: 3319719896477
  37. ↑ Risk-Thrombose.de
  38. ↑ Bauersachs R: [Prolonged Secondary Prevention After Venous Thromboembolism]. Dtsch Med Wochenschr 2018; 143: 137-142
  39. ↑ Weitz JI, Lensing AW, Prins MH, et al: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med 2017; 376: 1211-1222
  40. ↑ Mazzolai L, Aboyans V, Ageno W, et al: Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. Eur Heart J 2017:
  41. ↑ Hart C, Bauersachs R, Scholz U, et al: Prevention of VTE during Pregnancy and the Puerperium with a Special Focus on Women with Hereditary Thrombophilia or Prior VTE - Position Paper of the Working Group in Women's Health of the GTH. Hemostaseology 2020; 40:
  42. ↑ Linnemann B, Bauersachs R, Rott H, et al: Diagnosis of pregnancy-associated venous thromboembolism - position paper of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). Vasa 2016; 45: 87-101
  43. ↑ Linnemann B, Scholz U, Rott H, et al: Treatment of pregnancy-associated venous thromboembolism - position paper from the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). Vasa 2016; 45: 103-118
  44. ^ Mare P, Kiesel L, Bauersachs R, Beyer-Westendorf J, Bühling K: Hormonal Contraception. Guideline of the German Society of Gynecology and Obstetrics (S3-Level, AWMF Registry No. 015/015, December 2018). Working Group of Scientific Medical Societies (AWMF) 2019:
  45. ↑ Bauersachs R, von Heymann C, Kemkes-Matthes B, et al: Risk of bleeding and kidney function determine the procedure: Recommendations for the perioperative handling of direct oral anticoagulants (DOACs) and substances that inhibit platelet aggregation. Dtsch Arztebl 2019; 116.: A 1894-1898:
  46. ↑ Bauersachs R, Langer F, Kalka C, et al: Treatment of the antiphospholipid syndrome with direct oral anticoagulants Position statement of German societies. Vasa 2019; 48: 483-486:
  47. ↑ Pastori D, Eikelboom JW, Anand SS, et al: Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thromb Haemost 2019; 119: 576-585:
personal data
SURNAME Bauersachs, Rupert Martin
BRIEF DESCRIPTION German angiologist
DATE OF BIRTH 20th century